Why is Medicamen Biotec falling/rising?

As of 02-Jul, Medicamen Biotech Ltd is experiencing a decline in its stock price, currently at Rs 403.00, which represents a decrease of Rs 16.05 or 3.83%. The stock has underperformed its sector by 3.91% today, following a trend reversal after two consecutive days of gains. It reached an intraday low of Rs 399.8, reflecting a 4.59% drop. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. The company's delivery volume has also decreased significantly, falling by 53.8% compared to the 5-day average, which suggests a lack of investor interest. Over the past year, the stock has generated a return of -13.48%, with profits declining by 14.9%, highlighting ongoing financial struggles.
In the broader market context, Medicamen Biotech's short-term performance has been notably weaker than the benchmark, with a 1-week return of -1.98% compared to the Sensex's gain of 0.79%. This consistent underperformance against the benchmark over the last three years, coupled with poor long-term growth metrics such as a -16.39% annual decline in operating profit and a low return on capital employed (ROCE) of 5.30%, further exacerbates investor concerns. The stock's valuation appears expensive relative to its performance, and despite trading at a discount compared to peers, the overall sentiment remains negative due to declining sales and cash reserves.